General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SEPSZ
ADC Name
CN106459205B ADC-2
Synonyms
CN106459205B_ADC-2
   Click to Show/Hide
Organization
MedImmune LLC
Drug Status
Investigative
Indication
In total 1 Indication(s)
Prostate cancer [ICD11:2C82]
Investigative
Drug-to-Antibody Ratio
1.98
Antibody Name
Anti-EPHA2 mAb 1C1
 Antibody Info 
Antigen Name
Ephrin type-A receptor 2 (EPHA2)
 Antigen Info 
Payload Name
Undisclosed
Linker Name
CN106459205B ADC-2 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
42.2
ng/mL
CVCL_0105
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 42.20 ng/mL Positive EPHA2 expression (EPHA2+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Prostate carcinoma DU145 cells CVCL_0105
References
Ref 1 Conjugated compounds comprising cysteine engineered antibodies.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.